VERVE THERAPEUTICS, INC.
500 Technology Square, Suite 901
Cambridge, Massachusetts 02139
July 8, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Verve Therapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-265996
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Verve Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-265996), so that it may become effective at 4:30 p.m. Eastern time on July 12, 2022, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
| Very truly yours, | ||
| VERVE THERAPEUTICS, INC. | ||
| By: | /s/ Allison Dorval | |
| Name: Allison Dorval | ||
| Title: Chief Financial Officer | ||
| cc: | Craig Hilts, Wilmer Cutler Pickering Hale and Dorr LLP |